Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Nov 26;114(22):11305-47.
doi: 10.1021/cr500365f. Epub 2014 Nov 3.

Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis

Advait S Nagle  1 , Shilpi Khare  1 , Arun Babu Kumar, Frantisek Supek  1 , Andriy Buchynskyy, Casey J N Mathison  1 , Naveen Kumar Chennamaneni, Nagendar Pendem, Frederick S Buckner, Michael H Gelb, Valentina Molteni  1
Affiliations
Review

Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis

Advait S Nagle et al. Chem Rev. .
No abstract available

PubMed Disclaimer

Figures

Scheme 1
Scheme 1. Life Cycle of Leishmania Parasites (source: Public Health Image Library, provided by CDC- DPDx/Alexander J. da Silva, Ph.D., Blaine Mathison)
Figure 1
Figure 1
Current drugs used for treatment of leishmaniasis.
Figure 2
Figure 2
Drugs that have been repurposed for the treatment of leishmaniasis.
Figure 3
Figure 3
Novel scaffolds resulting from phenotypic screens.
Figure 4
Figure 4
Antileishmanial natural products and derivatives.
Figure 5
Figure 5
Antileishmanial benzoxazole and imidazole derivatives.
Figure 6
Figure 6
Antileishmanial chalcone derivatives.
Figure 7
Figure 7
Diamidine-containing leishmanicidal derivatives.
Figure 8
Figure 8
Dimers containing amino and aminoalcohol linkers.
Figure 9
Figure 9
Nitroheterocycles and organophosphate antileishmanial agents.
Figure 10
Figure 10
Antiparasitic triphenylmethane and rhodacyanine compounds.
Figure 11
Figure 11
Antileishmanial β-carboline and quinone derivatives.
Figure 12
Figure 12
Heterocyclic salts active against Leishmania.
Figure 13
Figure 13
Compounds containing pyrimidine/triazine pharmacophore.
Figure 14
Figure 14
Antiparasitic quinoline compounds.
Figure 15
Figure 15
Structures of imatinib (77) and berberine chloride (78).
Figure 16
Figure 16
Representative inhibitors of trypanothione, cyclophilin, and purine salvage pathways.
Figure 17
Figure 17
Representative examples of topoisomerase inhibitors.
Figure 18
Figure 18
Examples of protease and phosphodiesterase inhibitors.
Figure 19
Figure 19
Examples of tubulin inhibitors.
Figure 20
Figure 20
Established drugs to treat HAT.
Figure 21
Figure 21
Structure of SCYX-7158.
Figure 22
Figure 22
Amidine and diamidine compounds active against strains of T. brucei.
Figure 23
Figure 23
Miscellaneous anti-HAT compounds.
See this image and copyright information in PMC

References

    1. DNDi Home Page. http://www.dndi.org/diseases-projects/diseases/vl/tpp/tpp-vl.html. (accessed 08/31/2014).
    1. Manson-Bahr P. E. C.The Wellcome Trust illustrated history of tropical diseases; Cox F. E. G., Ed., The Wellcome Trust: London, U.K., 1996.
    1. Ross M. R.Report on the nature of kala azar; Office of the superintendent of government printing: Calcutta, India, 1899; pp 1–104.
    1. Hoare C. A. Trans. R. Soc. Trop. Med. Hyg. 1938, 32, 66.
    1. Nicolle C. C. R. Hebd. Seances Acad. Sci. 1908, 146, 842.

MeSH terms

Substances